Making better drugs: Decision gates in non-clinical drug development (Q35158006)

6 August 2017

1 reference

title

Making better drugs: Decision gates in non-clinical drug development (English)

1 reference

6 August 2017

J Fred Pritchard

1 reference

6 August 2017

Malle Jurima-Romet

1 reference

6 August 2017

Mark L J Reimer

1 reference

6 August 2017

Elisabeth Mortimer

1 reference

6 August 2017

Brenda Rolfe

1 reference

6 August 2017

Mitchell N Cayen

1 reference

6 August 2017

publication date

1 July 2003

1 reference

Nature Reviews Drug Discovery

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

542-553

1 reference

Changes in plasma protein binding have little clinical relevance

6 August 2017

cites work

1 reference

Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells

31 March 2020

1 reference

MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening

31 March 2020

1 reference

Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond

31 March 2020

1 reference

Hepatocyte growth factor and Madin-Darby canine kidney cells: in vitro models of epithelial cell movement and morphogenesis

31 March 2020

1 reference

Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes

31 March 2020

1 reference

High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay

31 March 2020

1 reference

Drug metabolites in safety testing

31 March 2020

1 reference

Advantages and disadvantages of using human cells for pharmacological and toxicological studies

31 March 2020

1 reference

Expression of Cytochromes P450 in Mammalian Cells

31 March 2020

1 reference

Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel

31 March 2020

1 reference

Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential

31 March 2020

1 reference

High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery

31 March 2020

1 reference

High-throughput screening approaches for investigating drug metabolism and pharmacokinetics

31 March 2020

1 reference

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers

31 March 2020

1 reference

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

31 March 2020

1 reference

Cytochrome P-450 3A4: regulation and role in drug metabolism

31 March 2020

1 reference

Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia

31 March 2020

1 reference

HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate

31 March 2020

1 reference

HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects

31 March 2020

1 reference

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

31 March 2020

1 reference

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

31 March 2020

1 reference

ADME/PK as part of a rational approach to drug discovery

31 March 2020

1 reference

Considerations in the design of toxicokinetic programs

31 March 2020

1 reference

Overview of Experimental Approaches for Study of Drug Metabolism and Drug-Drug Interactions

31 March 2020

1 reference

Nuclear Magnetic Resonance Spectroscopic and Principal Components Analysis Investigations into Biochemical Effects of Three Model Hepatotoxins

31 March 2020

1 reference

19F-NMR and directly coupled HPLC-NMR-MS investigations into the metabolism of 2-bromo-4- trifluoromethylaniline in rat: a urinary excretion balance study without the use of radiolabelling

31 March 2020

1 reference

Positron emission tomography in drug development and drug evaluation

31 March 2020

1 reference

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

31 March 2020

1 reference

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

31 March 2020

1 reference

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

31 March 2020

1 reference

A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro

31 March 2020

1 reference

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

31 March 2020

1 reference

An Introduction to Quadrupole Ion Trap Mass Spectrometry

31 March 2020

1 reference

An introduction to quadrupole-time-of-flight mass spectrometry

31 March 2020

1 reference

Liquid chromatography-nuclear magnetic resonance spectroscopy

31 March 2020

1 reference

Primary Hepatocyte Cultures as an in Vitro Experimental Model for the Evaluation of Pharmacokinetic Drug–Drug Interactions

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1131

1 reference

6 August 2017

1 reference